Dynavax Technologies
We have no price for Dynavax Technologies since 10 February 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Dynavax Technologies vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Dynavax Technologies | No profit yet | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Dynavax Technologies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
What analysts expect
- Average price target
- $27.00
- Range
- $20.00 – $32.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 19, 2026 | 0.05 | 0.08 | −38.5% |
| Nov 5, 2025 | 0.21 | 0.14 | +50.0% |
| Aug 7, 2025 | 0.14 | 0.12 | +16.7% |
| May 6, 2025 | -0.11 | 0.03 | −466.7% |
| Feb 20, 2025 | 0.05 | 0.05 | +0.0% |
| Nov 7, 2024 | 0.12 | 0.11 | +9.1% |
| Aug 6, 2024 | 0.08 | 0.06 | +33.3% |
| May 8, 2024 | -0.07 | -0.05 | −40.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Dynavax Technologies
Is Dynavax Technologies a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Dynavax Technologies AI analysis
What does Dynavax Technologies do?
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. It is in Drug Manufacturers - Specialty & Generic.
Who are Dynavax Technologies's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Dynavax Technologies's.
Prices: daily closes to Feb 10, 2026. Fundamentals: company reports via invest-like data.